HealthCap Portfolio Company Hemab Therapeutics raises $135M Series B Financing
HealthCap VIII portfolio company Hemab Therapeutics today announced the closing of an oversubscribed $135 million Series B financing. The round was led by Access Biotechnology with participation from new investors Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity. All current investors including HealthCap, Novo Holdings, and RA Capital Management also invested.
COPENHAGEN, DENMARK and BOSTON, MASS., US – February 21, 2023. Hemab Therapeutics is a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. The financing will support Hemab’s scientific and corporate growth plans through 2025, including completion of an ongoing Phase 1/2 clinical study of lead candidate HMB-001 in Glanzmann Thrombasthenia, initiation of pivotal studies, start and completion of Phase 1/2 clinical evaluation for HMB-VWF in von Willebrand disease, and future pipeline evolution in accordance with the company’s Hemab 1-2-5™ strategic guidance—targeting development of 5 clinical assets by 2025.
“Hemab is fundamentally reimagining the treatment paradigm for underserved bleeding and thrombotic disorders. This financing will allow us to progress our clinical programs for the first prophylactic treatments for Glanzmann Thrombasthenia and von Willebrand Disease, delivering functional cures for patients in need,” said Benny Sorensen, MD, PhD, CEO & President of Hemab. “We’re grateful for this robust syndicate of investors who support our approach of leveraging validated advanced technologies and deep insights into the biology of clotting to overcome decades of scientific stagnation.”
“Strong investor confidence—in this case, an upsized round and more than $200 million in demand—is a testament to the expertise of the Hemab team, their validated scientific approach, and the opportunity to bring long-overdue innovation to patients living with severe bleeding and thrombotic diseases,” said John Maraganore, PhD, Chair of Hemab’s Board of Directors.
“Hemab is a great example of HealthCap’s goal of being a long-term investor on diseases with high unmet medical needs and breakthrough therapies where we can truly make a difference for patients,” said Dr. Mårten Steen, MD, PhD, Managing Partner at HealthCap. “Hemab has made fantastic progress since we joined the company in 2021, and we look forward to continue working with the team.”
Hemab Therapeutics has been a part of HealthCap’s VIII fund since 2021.
HealthCap Contact
Mårten Steen, Managing Partner, HealthCap
marten.steen@healthcap.eu
+46 8 442 58 50
Hemab Contact
Benny Sørensen, CEO, Hemab
Media Contact
Lia Dangelico
ldangelico@vergescientific.com
+1 540-303-0180
About Hemab Therapeutics
Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in the US and Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance, Hemab 1-2-5TM, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with Factor VII Deficiency, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), Congenital Antithrombin III Deficiency, and other serious disorders. Learn more at hemab.com.
About HMB-001
HMB-001 is bispecific antibody that binds and stabilizes endogenous factor VIIa (FVIIa) with one antibody arm and TLT-1 on activated platelets with the other arm. This allows for accumulation of FVIIa in the body, recruitment of FVIIa directly to the surface of the activated platelets where it is known to facilitate clotting, and avoidance of clotting activity in the absence of tissue damage. HMB-001 was designed to be a first-in-class prophylactic treatment for Glanzmann Thrombasthenia with potential for other debilitating rare bleeding disorders. It entered Phase 1/2 clinical evaluation in late 2022, with initial data expected 2H 2023.
About HealthCap
HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions. HealthCap has built an impressive track record since the start in 1996 with investments in over 125 companies, and these companies have developed more than 30 pharmaceutical products to market approval.
Source: Hemab
